Business
Immunome Reports Full Year 2025 Financial Results and Provides Business Update
BOTHELL, Wash., March 03, 2026--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2025, and provided a business update.
About this update from Immunome, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":334,"url":"https://media.zenfs.com/en/business-wire.com/188fece8b87f761ea71b122920cd1ec6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CSOWkmG2lwFSHLU3_tCRmQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY2ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/188fece8b87f761ea71b122920cd1ec6","width":480,"height":334}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026","length":100,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"IM-1021 Phase 1 ongoing with initial data expected in 2026","length":58,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Three IND submissions for solid tumor-targeted ADC programs planned in 2026","length":75,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Underwritten public offering in December 2025 raised $460.5 million in gross proceeds, extending projected cash runway into 2028","length":128,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":361,"olType":false},{"type":"text","content":"BOTHELL, Wash., March 03, 2026--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2025, and provided a business update.","length":294,"tagName":"p"},{"type":"text","content":""Immunome made substantial progress in 2025. The positive Phase 3 RINGSIDE results represent a significant milestone for patients living with desmoid tumors and will support our planned NDA submission for varegacestat in the second quarter of 2026," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome. "We are focused on the regulatory, manufacturing, and commercial readiness activities necessary to position the program for approval and launch."","length":495,"tagName":"p"},{"type":"text","content":""We continue to advance our antibody-drug conjugate pipeline, with the Phase 1 study of IM-1021 ongoing. Over the course of 2026, we expect to submit INDs for three differentiated solid tumor AD...